Repligen
RGEN
#1855
Rank
โ‚ฌ10.07 B
Marketcap
157,59ย โ‚ฌ
Share price
6.68%
Change (1 day)
22.59%
Change (1 year)
Categories

P/S ratio for Repligen (RGEN)

P/S ratio as of November 2026 (TTM): 12.9

According to Repligen 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 4.91. At the end of 2026 the company had a P/S ratio of 12.7.

P/S ratio history for Repligen from 2001 to 2026

PS ratio at the end of each year

Year P/S ratio Change
202612.71.57%
202512.5-2.5%
202412.9-20.43%
202316.237.72%
202211.7-46.29%
202121.8-23.72%
202028.660.6%
201917.849.33%
201811.96.67%
201711.212.2%
20169.97-10.61%
201511.29.27%
201410.259.86%
20136.39103.04%
20123.15-8.06%
20113.42-37.77%
20105.50-10%
20096.1145.49%
20084.20-59.34%
200710.360.41%
20066.44-30.4%
20059.25-9.44%
200410.2-46.53%
200319.166.56%
200211.5-35.84%
200117.9

P/S ratio for similar companies or competitors

Company P/S ratio P/S ratio differencediff. Country
Pfizer
PFE
2.55-80.18%๐Ÿ‡บ๐Ÿ‡ธ USA
Thermo Fisher Scientific
TMO
5.37-58.24%๐Ÿ‡บ๐Ÿ‡ธ USA
General Electric
GE
6.42-50.15%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
2.51-80.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Sangamo Therapeutics
SGMO
0.8872-93.11%๐Ÿ‡บ๐Ÿ‡ธ USA
Novavax
NVAX
3.17-75.33%๐Ÿ‡บ๐Ÿ‡ธ USA
Neurocrine Biosciences
NBIX
4.54-64.74%๐Ÿ‡บ๐Ÿ‡ธ USA
Bio-Techne
TECH
9.39-27.03%๐Ÿ‡บ๐Ÿ‡ธ USA
BioMarin Pharmaceutical
BMRN
3.10-75.91%๐Ÿ‡บ๐Ÿ‡ธ USA
Charles River Laboratories
CRL
4.00-68.90%๐Ÿ‡บ๐Ÿ‡ธ USA